PolyPeptide Aktie
| 17,50CHF | 0,02CHF | 0,11% |
WKN DE: A3CNHV / ISIN: CH1110760852
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 973 | 1 101 | 1 219 | 1 273 | 1 362 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,25 | 0,28 | 0,23 | 0,24 | 0,24 |
Bilanz (in Mio. CHF) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 195 | 344 | 248 | 304 | 308 |
| Summe Anlagevermögen | 212 | 273 | 320 | 337 | 402 |
| Summe Aktiva | 407 | 617 | 569 | 641 | 710 |
Bilanz (in Mio. CHF) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 214 | 180 | 152 | 286 | 375 |
| Summe Eigenkapital | 192 | 436 | 416 | 354 | 335 |
| Summe Passiva | 407 | 617 | 569 | 641 | 710 |
Adresse
| Neuhofstrasse 24, 6340 Baar | |
| Telefon | +41 (43) 502-05-80 |
| Internet | http://www.polypeptide.com |
Management
|
Beat In-Albon
Independent Non-Executive Director |
|
Christina del Vecchio
Secretary & General Counsel |
|
Erik Schropp
Non-Executive Director |
|
Jane Anne Salik
Non-Executive Director |
|
Jens Fricke
Director-Global Operations |
|
Jon Holbech Rasmussen
Director-Global Development, IP & Regulatory |
|
Juan-José Gonzalez
Chief Executive Officer |
|
Marc Augustin
Chief Financial Officer |
|
Michael Stäheli
Head-Investor Relations & Corporate Communications |
|
Monika Casanova
Chief Human Resources Officer |
|
Neil James Thompson
Director-Global Sales & Marketing |
|
Olivier Ludemann-Hombourger
Director-Global Innovation & Technology |
|
Patrick Aebischer
Vice Chairman |
|
Peter Wilden
Chairman |
|
Philippe A. Weber
Independent Non-Executive Director |
|
Stéphane Varray
Chief Commercial Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.